TLDR: Giles AI has commercially launched ‘giles,’ an AI-powered research agent designed to significantly accelerate research in healthcare, clinical, and medical sectors. The tool extracts, analyzes, summarizes, and references information from verified medical databases and private files, boasting up to 94% accuracy and availability in over 40 languages. It aims to streamline literature review and enhance workflows in areas like drug discovery and development.
Giles AI, a company dedicated to making advanced research tools accessible and simplifying data interaction for scientists, has officially announced the commercial launch of its specialized AI research agent, ‘giles.’ This innovative platform is engineered to expedite research processes across the healthcare, clinical, and broader life science sectors.
The giles AI agent is designed to extract, analyze, summarize, and reference information from a wide array of sources, including verified medical databases and private institutional files. This capability facilitates rapid literature review, a traditionally time-consuming aspect of scientific inquiry. The company highlights that giles operates with an LLM-agnostic approach, optimizing research intelligence for scientific text comprehension, data accuracy validation, citation tracking, and domain-specific language understanding crucial for medical, clinical, and academic environments.
One of the key benefits touted by Giles AI is the agent’s ability to search trusted information sources, including personal documents, to generate easily digestible abstracts and comparative analyses of relevant data. Furthermore, it cites and verifies its results, all within a matter of seconds. The company claims an impressive accuracy rate of up to 94% and states that the agent is available in over 40 languages, making it a versatile tool for global research efforts.
The applications for giles span all facets of life science and healthcare research, including critical areas such as drug discovery and development. Here, the tool is expected to enhance workflows by providing researchers with access to real-time insights, thereby accelerating the pace of innovation.
The development and subsequent commercialization of the giles AI agent were supported through a strategic partnership with Regulatory Scientific and Health Solutions (R-S-S), a prominent entity in health economics and drug development. This collaboration was instrumental in connecting researchers with open-access medical databases. Giles AI also receives ongoing support from Google UK and has established high-profile collaborations with various pharmaceutical companies, further integrating researchers directly with essential medical databases.
Also Read:
- Innovate UK Launches £1 Million Agentic AI Pioneers Prize to Drive Breakthroughs in Key UK Industries
- Navigating the AI Hype Cycle in Healthcare: Industry Leaders and Media Weigh In on Practicality and Ethics
A spokesperson for Giles AI emphasized the transformative potential of the new agent, stating, “giles is transforming the way we approach medical research literature review. Instead of spending hours researching, analysing, and organising data, users can simply ask our innovative AI agent, making healthcare research effortless. We are excited to share giles with both academics and researchers from across sector as we advance in our mission to make advanced AI research tools available to all, and look forward to seeing the scientific breakthroughs our technology facilitates.”
